Tags

Type your tag names separated by a space and hit enter

CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Anticancer Res. 2002 Jul-Aug; 22(4):2311-6.AR

Abstract

BACKGROUND

CEA, CA 19-9, CA 242 and CA 72-4 are commonly used tumour markers for gastrointestinal malignancies. The advantage of the concomitant use of these markers is under debate.

MATERIALS AND METHODS

Serum concentrations of the markers were measured at the time of diagnosis in 161 patients with benign and 125 with malignant gastrointestinal diseases. Concomitant use of the markers was evaluated in a logistic regression model.

RESULTS

CA 19-9, CA 242 or CA 72-4 showed similar sensitivity of 44% for gastric cancer, whereas CEA was elevated in 25% of the cases. In patients with colorectal cancer, CEA was most frequently elevated (54%), followed by CA 242 (46%), CA 19-9 (36%) and CA 72-4 (25%). High CA 19-9 and CA 242 serum levels were frequent in patients with cholangiocarcinoma (86% and 68%, respectively) and pancreatic cancer (80% and 63%, respectively). In the benign disease group, serum CA 19-9 was most frequently elevated, i.e. in 24%, 25% and 38% of patients with pancreatic, biliary and liver disorders, respectively. The overall accuracy of CEA, CA 19-9, CA 242 and CA 72-4 was 66%, 71%, 71% and 66%, respectively (p > 0.18). When combined in a logistic regression model, CA 72-4, CA 19-9 and CEA provided independent diagnostic information, whereas CA 242 contributed with independent diagnostic information only on excluding CA 19-9. The probability of cancer for each patient, calculated with the model, was applied as a diagnostic test and was compared with the single markers by ROC-curve analysis. The AUC value of the probability index was significantly higher than the values of the different tumour markers.

CONCLUSION

An algorithm based on the combination of CEA, CA 19-9 and CA 72-4 improved the diagnostic accuracy in gastrointestinal tract malignancies compared with these markers alone.

Authors+Show Affiliations

Department of Surgery, Helsinki University Central Hospital, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12174919

Citation

Carpelan-Holmström, M, et al. "CEA, CA 19-9 and CA 72-4 Improve the Diagnostic Accuracy in Gastrointestinal Cancers." Anticancer Research, vol. 22, no. 4, 2002, pp. 2311-6.
Carpelan-Holmström M, Louhimo J, Stenman UH, et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 2002;22(4):2311-6.
Carpelan-Holmström, M., Louhimo, J., Stenman, U. H., Alfthan, H., & Haglund, C. (2002). CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Research, 22(4), 2311-6.
Carpelan-Holmström M, et al. CEA, CA 19-9 and CA 72-4 Improve the Diagnostic Accuracy in Gastrointestinal Cancers. Anticancer Res. 2002 Jul-Aug;22(4):2311-6. PubMed PMID: 12174919.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. AU - Carpelan-Holmström,M, AU - Louhimo,J, AU - Stenman,U H, AU - Alfthan,H, AU - Haglund,C, PY - 2002/8/15/pubmed PY - 2002/9/14/medline PY - 2002/8/15/entrez SP - 2311 EP - 6 JF - Anticancer research JO - Anticancer Res. VL - 22 IS - 4 N2 - BACKGROUND: CEA, CA 19-9, CA 242 and CA 72-4 are commonly used tumour markers for gastrointestinal malignancies. The advantage of the concomitant use of these markers is under debate. MATERIALS AND METHODS: Serum concentrations of the markers were measured at the time of diagnosis in 161 patients with benign and 125 with malignant gastrointestinal diseases. Concomitant use of the markers was evaluated in a logistic regression model. RESULTS: CA 19-9, CA 242 or CA 72-4 showed similar sensitivity of 44% for gastric cancer, whereas CEA was elevated in 25% of the cases. In patients with colorectal cancer, CEA was most frequently elevated (54%), followed by CA 242 (46%), CA 19-9 (36%) and CA 72-4 (25%). High CA 19-9 and CA 242 serum levels were frequent in patients with cholangiocarcinoma (86% and 68%, respectively) and pancreatic cancer (80% and 63%, respectively). In the benign disease group, serum CA 19-9 was most frequently elevated, i.e. in 24%, 25% and 38% of patients with pancreatic, biliary and liver disorders, respectively. The overall accuracy of CEA, CA 19-9, CA 242 and CA 72-4 was 66%, 71%, 71% and 66%, respectively (p > 0.18). When combined in a logistic regression model, CA 72-4, CA 19-9 and CEA provided independent diagnostic information, whereas CA 242 contributed with independent diagnostic information only on excluding CA 19-9. The probability of cancer for each patient, calculated with the model, was applied as a diagnostic test and was compared with the single markers by ROC-curve analysis. The AUC value of the probability index was significantly higher than the values of the different tumour markers. CONCLUSION: An algorithm based on the combination of CEA, CA 19-9 and CA 72-4 improved the diagnostic accuracy in gastrointestinal tract malignancies compared with these markers alone. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/12174919/CEA_CA_19_9_and_CA_72_4_improve_the_diagnostic_accuracy_in_gastrointestinal_cancers_ L2 - https://www.lens.org/lens/search?q=citation_id:12174919 DB - PRIME DP - Unbound Medicine ER -